


Appendix 1 (as supplied by the authors): Supplementary material

Supplementary Table S1: TDP drugs by drug groups.

Cytotoxic chemotherapy	LHRH agonist	Aromatase inhibitor	Antiandrogen	Supportive therapy
asparaginase	buserelin	aminoglutethimide	bicalutamide	antidiarrheals
busulfan	goserelin	anastrozole	cyproterone	antiemetics
carmustine	leuprolide	exemestane	flutamide	bisphosphonates
chlorambucil	triptorelin	letrozole	nilutamide	corticosteroids
cladribine				erythropoiesis-stimulating agents (ESA)
cyclophosphamide				granulocyte colony-stimulating factors (GCSF)
cytarabine				iron
dacarbazine				laxatives
daunorubicin				adjunct pain medications
epirubicin				opiates
estramustine				somatostatins
etoposide				
fludarabine				
fluorouracil				
hydroxyurea				
irinotecan				
lomustine				
mechlorethamine				
melphalan				
mercaptopurine				
methotrexate				
mitomycin				
mitotane				

procarbazine				
thioguanine				
thiotepa				
vinblastine				



Supplementary Figure S1: Proportion of total annual cost, highlighting select cancer treatment drugs in TDP, 1997-2016, adjusted for inflation to 2016.